Literature DB >> 10772648

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.

D Hanahan1, G Bergers, E Bergsland.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10772648      PMCID： PMC300842          DOI： 10.1172/JCI9872

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  20 in total

Review 1.  Replication-selective adenoviruses as oncolytic agents.

Authors:  C Heise; D H Kirn
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  The hallmarks of cancer.

Authors:  D Hanahan; R A Weinberg
Journal:  Cell       Date:  2000-01-07       Impact factor: 41.582

3.  Antiangiogenesis is produced by nontoxic doses of vinblastine.

Authors:  A Vacca; M Iurlaro; D Ribatti; M Minischetti; B Nico; R Ria; A Pellegrino; F Dammacco
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

4.  Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Authors:  G Klement; S Baruchel; J Rak; S Man; K Clark; D J Hicklin; P Bohlen; R S Kerbel
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule.

Authors:  J W Slaton; P Perrotte; K Inoue; C P Dinney; I J Fidler
Journal:  Clin Cancer Res       Date:  1999-10       Impact factor: 12.531

Review 6.  COX-2 inhibitors. A new class of antiangiogenic agents.

Authors:  J L Masferrer; A Koki; K Seibert
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

7.  Long-term continuous 5-fluorouracil infusion in patients with advanced head and neck cancer.

Authors:  P Sørensen; L J Andersen; O Hansen; L Bastholt
Journal:  Acta Oncol       Date:  1999       Impact factor: 4.089

8.  Safety and antitumor activity of recombinant soluble Apo2 ligand.

Authors:  A Ashkenazi; R C Pai; S Fong; S Leung; D A Lawrence; S A Marsters; C Blackie; L Chang; A E McMurtrey; A Hebert; L DeForge; I L Koumenis; D Lewis; L Harris; J Bussiere; H Koeppen; Z Shahrokh; R H Schwall
Journal:  J Clin Invest       Date:  1999-07       Impact factor: 14.808

9.  Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth.

Authors:  D Ingber; T Fujita; S Kishimoto; K Sudo; T Kanamaru; H Brem; J Folkman
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

10.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

Authors:  T Browder; C E Butterfield; B M Kräling; B Shi; B Marshall; M S O'Reilly; J Folkman
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701
View more
  190 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.

Authors:  Guido Bocci; Giulio Francia; Shan Man; Jack Lawler; Robert S Kerbel
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-15       Impact factor: 11.205

3.  Vasohibin: the feedback on a new inhibitor of angiogenesis.

Authors:  Robert S Kerbel
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

4.  Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.

Authors:  William M Merritt; Alpa M Nick; Amy R Carroll; Chunhua Lu; Koji Matsuo; Melissa Dumble; Nicholas Jennings; Shuyun Zhang; Yvonne G Lin; Whitney A Spannuth; Aparna A Kamat; Rebecca L Stone; Mian M K Shahzad; Robert L Coleman; Rakesh Kumar; Anil K Sood
Journal:  Mol Cancer Ther       Date:  2010-04-06       Impact factor: 6.261

5.  Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration.

Authors:  Alessandro Grattoni; Haifa Shen; Daniel Fine; Arturas Ziemys; Jaskaran S Gill; Lee Hudson; Sharath Hosali; Randy Goodall; Xuewu Liu; Mauro Ferrari
Journal:  Pharm Res       Date:  2010-07-01       Impact factor: 4.200

6.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

7.  Experimental study on therapeutic effect of in vivo expression of Cell I-Hep II recombinant polypeptide of fibronectin on murine H22 hepatocellular carcinoma.

Authors:  Gui-Mei Zhang; Yan Yang; Bo Huang; Hui Xiao; Dong Li; Zuo-Hua Feng
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

8.  FOXL2 suppresses proliferation, invasion and promotes apoptosis of cervical cancer cells.

Authors:  Xing-Long Liu; Yu-Han Meng; Jian-Li Wang; Biao-Bing Yang; Fan Zhang; Sheng-Jian Tang
Journal:  Int J Clin Exp Pathol       Date:  2014-03-15

Review 9.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

10.  Center of cancer systems biology second annual workshop--tumor metronomics: timing and dose level dynamics.

Authors:  Philip Hahnfeldt; Lynn Hlatky; Giannoula Lakka Klement
Journal:  Cancer Res       Date:  2013-03-14       Impact factor: 12.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.